ERBB3 and melanoma: Treatment with the two FDA-approved compounds gefitinib (EGFR inhibitor) and lapatinib (ErbB2/EGFR inhibitor), or with anti-ErbB3 mAb can overcome ErbB-mediated resistance to BRAF or MEK inhibitors (PLX4720 or single/combined vemurafenib and trametinib), diminishing melanoma cells growth both in vitro and in vivo (110–112); this effect was associated with synergistically reduced pAkt and pERK (111,112).